These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35285351)

  • 1. Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis.
    Radtke KK; Svensson EM; van der Laan LE; Hesseling AC; Savic RM; Garcia-Prats AJ
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):161-174. PubMed ID: 35285351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
    Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
    Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
    Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
    Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis.
    Mezochow A; Thakur KT; Zentner I; Subbian S; Kagan L; Vinnard C
    Int J Infect Dis; 2019 Jul; 84():15-21. PubMed ID: 31051278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xpert
    Kohli M; Schiller I; Dendukuri N; Dheda K; Denkinger CM; Schumacher SG; Steingart KR
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012768. PubMed ID: 30148542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of high-dose rifampicin in the management of tuberculosis meningitis: Systematic review and meta-analysis.
    Charlie L; Abay SM; Tesfaye A; Mlera RN; Mwango S; Goretti M
    Int J Mycobacteriol; 2021; 10(3):312-319. PubMed ID: 34494572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
    Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
    J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.
    Wasserman S; Davis A; Stek C; Chirehwa M; Botha S; Daroowala R; Bremer M; Maxebengula M; Koekemoer S; Goliath R; Jackson A; Crede T; Naude J; Szymanski P; Vallie Y; Moosa MS; Wiesner L; Black J; Meintjes G; Maartens G; Wilkinson RJ
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0014021. PubMed ID: 33972248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.
    Ruslami R; Gafar F; Yunivita V; Parwati I; Ganiem AR; Aarnoutse RE; Wilffert B; Alffenaar JC; Nataprawira HM
    Arch Dis Child; 2022 Jan; 107(1):70-77. PubMed ID: 34183327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
    Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
    Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
    Kwara A; Ramachandran G; Swaminathan S
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):55-68. PubMed ID: 19968575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
    Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
    Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials.
    Svensson EM; Dian S; Te Brake L; Ganiem AR; Yunivita V; van Laarhoven A; Van Crevel R; Ruslami R; Aarnoutse RE
    Clin Infect Dis; 2020 Nov; 71(8):1817-1823. PubMed ID: 31665299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients.
    Yunivita V; Dian S; Ganiem AR; Hayati E; Hanggono Achmad T; Purnama Dewi A; Teulen M; Meijerhof-Jager P; van Crevel R; Aarnoutse R; Ruslami R
    Int J Antimicrob Agents; 2016 Oct; 48(4):415-21. PubMed ID: 27526979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The quest to deliver high-dose rifampicin: can the inhaled approach help?
    Khadka P; Dummer J; Hill PC; Das SC
    Expert Opin Drug Deliv; 2024; 21(1):31-44. PubMed ID: 38180078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.
    Khadka P; Dummer J; Hill PC; Katare R; Das SC
    Drug Deliv Transl Res; 2023 May; 13(5):1246-1271. PubMed ID: 36131190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.